| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785867 | Cancer Treatment Reviews | 2018 | 10 Pages |
Abstract
Anti-PD-1/PD-L1 antibodies have shown encouraging clinical activity in advanced GC/GEJC. Results from ongoing phase 3 trials are needed to further evaluate the potential roles of these agents within the continuum of care.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Julien Taieb, Markus Moehler, Narikazu Boku, Jaffer A. Ajani, Eduardo Yañez Ruiz, Min-Hee Ryu, Silke Guenther, Vikram Chand, Yung-Jue Bang,